Spots Global Cancer Trial Database for inhibitor
Every month we try and update this database with for inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | NCT00777504 | Renal Cell Carc... Gastrointestina... | usage oral angi... stop oral angio... | 18 Years - | Radboud University Medical Center | |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | NCT04322383 | Hairy Cell Leuk... | binimetinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | NCT00777504 | Renal Cell Carc... Gastrointestina... | usage oral angi... stop oral angio... | 18 Years - | Radboud University Medical Center | |
| Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | NCT01140568 | Glioma | nilotinib | 18 Years - | University of California, San Diego | |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | NCT04324112 | Hairy Cell Leuk... | binimetinib Encorafenib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | NCT00894894 | Solid Tumors | MP-470 amuvatinib (MP-... | 18 Years - 70 Years | Astex Pharmaceuticals, Inc. | |
| A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease | NCT00001341 | Neoplasm | ZD1694 (TOMUDEX... | - | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment | NCT00688376 | Attention Impai... | Donepezil hydro... Placebo | 6 Years - 17 Years | Eisai Inc. | |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | NCT00777504 | Renal Cell Carc... Gastrointestina... | usage oral angi... stop oral angio... | 18 Years - | Radboud University Medical Center | |
| A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease | NCT00001341 | Neoplasm | ZD1694 (TOMUDEX... | - | National Institutes of Health Clinical Center (CC) | |
| Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) | NCT00989261 | Acute Myeloid L... | Compound AC220 | 18 Years - 85 Years | Daiichi Sankyo | |
| Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | NCT05472506 | Head and Neck S... Head and Neck C... Head Cancer Neck Cancer Head Cancer Nec... Neck Carcinoma | IK-175 + nivolu... | 18 Years - | Ikena Oncology | |
| Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy | NCT05977673 | Hodgkin Lymphom... | Tislelizumab | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | NCT00777504 | Renal Cell Carc... Gastrointestina... | usage oral angi... stop oral angio... | 18 Years - | Radboud University Medical Center | |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | NCT04794699 | Solid Tumor | IDE397 Docetaxel Paclitaxel Sacituzumab gov... | 18 Years - | IDEAYA Biosciences | |
| Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | NCT00894894 | Solid Tumors | MP-470 amuvatinib (MP-... | 18 Years - 70 Years | Astex Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
